Cargando…

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients

BACKGROUND: Post-transplant lymphoproliferative disorder is a well-recognized but rare complication of hematopoietic stem cell and solid organ transplant. Due to rarity of this disease, retrospective studies from major transplant centers has been the main source to provide treatment guidelines, whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bishnoi, Rohit, Bajwa, Ravneet, Franke, Aaron J., Skelton, William Paul, Wang, Yu, Patel, Niraj M., Slayton, William Birdsall, Zou, Fei, Dang, Nam H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622441/ https://www.ncbi.nlm.nih.gov/pubmed/29021921 http://dx.doi.org/10.1186/s40164-017-0087-0

Ejemplares similares

Single-institution Retrospective Analysis of Prognostic Factors Influencing Very Late-onset Post-transplant Lymphoproliferative Disorder
por: Bishnoi, Rohit, et al.
Publicado: (2020)

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) IN RENAL TRANSPLANT PATIENTS WITH COVID-19
por: MAHONEY, IAN, et al.
Publicado: (2022)

O01 Post-transplant lymphoproliferative disorder (PTLD) in a patient with rheumatoid arthritis
por: Kim, Sung-Hee, et al.
Publicado: (2021)

Post-transplant Lymphoproliferative Disorder (PTLD) in the US Population: Demographics, Treatment Characteristics, and Survival Analysis
por: Ullah, Asad, et al.
Publicado: (2023)

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)
por: Kline, Kathryn, et al.
Publicado: (2023)

Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
por: Clerico, Michele, et al.
Publicado: (2022)

PD‐L1 and PD1 expression in post‐transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter‐ and intra‐individual descriptive study covering the whole spectrum of PTLD categories
por: Schiefer, Ana‐Iris, et al.
Publicado: (2019)

Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients
por: Liu, Yan, et al.
Publicado: (2023)

Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
por: Zimmermann, Heiner, et al.
Publicado: (2022)

A case of post renal transplant PTLD of lung
por: Sinha, Tanay, et al.
Publicado: (2023)

Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD)
por: Hong, Jennifer, et al.
Publicado: (2021)

Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein–Barr Virus (EBV) Assessments—A Single Tertiary Referral Center Experience and Review of Literature
por: Lau, Eric, et al.
Publicado: (2021)

Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives
por: Compagno, Francesca, et al.
Publicado: (2020)

A Multi-Center Retrospective Analysis Examining the Effect of Dipeptidyl Peptidase-4 Inhibitors on Progression-Free Survival in Patients With Prostate Cancer
por: Pan, Kelsey, et al.
Publicado: (2021)

Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer
por: Nguyen, Thu-Cuc, et al.
Publicado: (2018)

Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation
por: Janardan, Sanyukta, et al.
Publicado: (2022)

Immunology of THymectomy And childhood CArdiac transplant (ITHACA): protocol for a UK-wide prospective observational cohort study to identify immunological risk factors of post-transplant lymphoproliferative disease (PTLD) in thymectomised children
por: Offor, Ugonna T, et al.
Publicado: (2023)

Expert Consensus on the Characteristics of Patients with Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV(+) PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study
por: Chaganti, Sridhar, et al.
Publicado: (2023)

Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD
por: Oren, Daniel, et al.
Publicado: (2022)

Use of Foscarnet Therapy for EBV Infection following Control of PTLD with Enhancement of Cellular Immunity in a Lung-Transplant Recipient
por: Afshar, Kamyar, et al.
Publicado: (2011)

Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation
por: Rausch, Lisa, et al.
Publicado: (2016)

PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis
por: Stravodimou, A., et al.
Publicado: (2012)

Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study
por: Bishnoi, Rohit, et al.
Publicado: (2019)

Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer
por: Shah, Chintan, et al.
Publicado: (2020)

Late Onset Graft Plasmacytoma-Like PTLD Presenting as Acute Hyperglycemia in a Kidney-Pancreas Transplant Recipient
por: Ventura-Aguiar, P., et al.
Publicado: (2019)

Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population
por: Ali, Hatem, et al.
Publicado: (2020)

Sterile necrotizing and non-necrotizing granulomas in a heart transplant patient with history of PTLD: A unique finding
por: Piening, Nicholas, et al.
Publicado: (2019)

Analysis of Overall Survival in Patients With Multiple Primary Malignancies: A Single-center Experience
por: Skelton, William P, et al.
Publicado: (2019)

Post-transplant lymphoproliferative disease
por: Dharnidharka, Vikas R., et al.
Publicado: (2009)

Does rabbit anti-thymocyte globulin dose and antiviral prophylaxis alter the risk of the development of PTLD in renal transplant population?
por: Mohamed, Mahmoud, et al.
Publicado: (2020)

High Predictive Value of the Soluble ZEBRA Antigen (Epstein-Barr Virus Trans-Activator Zta) in Transplant Patients with PTLD
por: Lupo, Julien, et al.
Publicado: (2022)

Ocular post-transplant lymphoproliferative disorder
por: Chen, Yun-Wen, et al.
Publicado: (2015)

Post-transplant lymphoproliferative disease of the larynx
por: Vandjelovic, Nathan D, et al.
Publicado: (2019)

Management of post-transplant lymphoproliferative disorders
por: Dierickx, Daan, et al.
Publicado: (2019)

P1346: EVALUATION OF CURRENT NATIONAL PRACTICE IN THE PREVENTION OF PTLD POST PAEDIATRIC HSCT
por: Kissane, E., et al.
Publicado: (2022)

HLA-E–restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD
por: Vietzen, Hannes, et al.
Publicado: (2023)

Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation
por: Asleh, Rabea, et al.
Publicado: (2022)

Posttransplant Lymphoproliferative Disease after Lung Transplantation
por: Neuringer, Isabel P.
Publicado: (2013)

Post-transplantation lymphoproliferative disorder with gastrointestinal involvement
por: Inayat, Faisal, et al.
Publicado: (2018)

A Unique “Composite” PTLD with Diffuse Large B-Cell and T/Anaplastic Large Cell Lymphoma Components Occurring 17 Years after Transplant
por: La Fortune, Kristin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i0udhjna8vh96cbsie35apscqh